Mumbai, July 11 -- Anthem Biosciences, an innovation-led contract research, development, and manufacturing organization (CRDMO), is set to launch its Rs.3,395-crore initial public offering (IPO) on Monday.

The offer-for-sale (OFS), priced between Rs.540 and Rs.570 per share, marks a key milestone for the company, which has demonstrated strong revenue growth, international expansion, and improving profitability over the past three years.

Having executed over 8,000 drug development projects for more than 675 clients across 44 countries, Anthem has built a solid position in the new chemical entity (NCE) and new biological entity (NBE) segments.

The company's services cater to over 550 pharmaceutical and biotech clients, primarily in the U...